A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; VRC 01LS (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2019 Planned End Date changed from 30 Sep 2021 to 29 Mar 2022.
- 26 Dec 2018 Planned initiation date changed from 31 Jan 2019 to 15 Mar 2019.
- 22 Nov 2018 New trial record